Bioadaptives (BDPT) Equity Average (2016 - 2025)
Bioadaptives' Equity Average history spans 7 years, with the latest figure at -$1.8 million for Q4 2025.
- On a quarterly basis, Equity Average fell 9.97% to -$1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.8 million, a 9.97% decrease, with the full-year FY2025 number at -$1.8 million, down 15.54% from a year prior.
- Equity Average hit -$1.8 million in Q4 2025 for Bioadaptives, down from -$1.3 million in the prior quarter.
- Over the last five years, Equity Average for BDPT hit a ceiling of -$1.2 million in Q4 2021 and a floor of -$1.8 million in Q3 2024.
- Historically, Equity Average has averaged -$1.5 million across 5 years, with a median of -$1.5 million in 2022.
- Biggest five-year swings in Equity Average: crashed 32.73% in 2021 and later rose 26.59% in 2025.
- Tracing BDPT's Equity Average over 5 years: stood at -$1.2 million in 2021, then plummeted by 32.19% to -$1.5 million in 2022, then increased by 8.36% to -$1.4 million in 2023, then dropped by 17.07% to -$1.6 million in 2024, then dropped by 9.97% to -$1.8 million in 2025.
- Business Quant data shows Equity Average for BDPT at -$1.8 million in Q4 2025, -$1.3 million in Q3 2025, and -$1.4 million in Q2 2025.